EAST HANOVER, N.J., June 1, 2021 /PRNewswire/ — Novartis, a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx (R) ...

Cosentyx (secukinumab) is a brand-name injection prescribed for plaque psoriasis and certain types of arthritis. It works to treat these conditions by slowing down an overactive immune system.

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment. Serious ...

Cosentyx (secukinumab) is used to treat certain autoimmune conditions. If you’re stopping treatment or switching drugs, you may wonder how long Cosentyx stays in your system. Keep reading to learn ...

The approval was based on data from the phase 3 SUNSHINE and SUNRISE trials, which included 1084 adults with moderate to severe HS. Results showed a significantly greater proportion of patients ...

The price you pay for Cosentyx may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the cost ...

Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November. The drug’s manufacturer, Novartis, said Sept.